Zolbetuximab plus chemotherapy versus immune checkpoint inhibitor regimens by programmed death-ligand 1 combined positive score in locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: a Bayesian network meta-analysis. (PubMed, ESMO Open) - Sep 17, 2026 - "These findings support a biomarker-informed treatment approach in human epidermal growth factor receptor 2 (HER2)-negative, CLDN18.2-positive advanced gastric/GEJ adenocarcinoma. In PD-(L)1 CPS ≥1 to <10, zolbetuximab plus chemotherapy demonstrated consistent efficacy and may represent a relevant option beyond PD-(L)1-driven selection. In CPS ≥10, zolbetuximab remained clinically meaningful, with efficacy comparable to select ICI-based regimens when exposure is optimized. Results should be interpreted cautiously given these are indirect comparisons and warrant confirmation in prospective studies."
Checkpoint inhibition • IO biomarker • Journal • Retrospective data • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • CLDN18 • HER-2 • PD-L1
|
|
F Lordick; G Gourgioti; H Yang; K Shitara; M Oh; R H Getzenberg; R Ranganath; S J Klempner; S Y Rha; X Chai
|